Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Circulating miRNAs and their applications for early diagnosis of acute coronary syndrome

A technology for early diagnosis of coronary syndrome, applied in the direction of DNA/RNA fragments, recombinant DNA technology, microbial measurement/testing, etc., can solve problems that are difficult to treat as acute coronary syndrome, and achieve high sensitivity and high specificity sexual effect

Active Publication Date: 2017-03-08
FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the earliest of these miRNAs can only be detected 4 hours after the onset of symptoms of acute myocardial infarction, making it difficult for these miRNAs to be used as early diagnostic biomarkers for acute coronary syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Circulating miRNAs and their applications for early diagnosis of acute coronary syndrome
  • Circulating miRNAs and their applications for early diagnosis of acute coronary syndrome
  • Circulating miRNAs and their applications for early diagnosis of acute coronary syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1, miRNA chip analysis verifies the expression difference of the markers of the present invention between the healthy group and the high-risk group

[0056] In the present embodiment, a total of 32 cases of acute coronary syndrome and healthy controls were collected, divided into a healthy group, a high-risk group, an unstable angina pectoris group and an acute myocardial infarction group (8 cases in each group). Significant difference (see Table 1).

[0057] Table 1. miRNA chip analysis of clinical characteristics of samples in each group

[0058]

[0059] miR-3149, miR-122, miR-2861, miR-140-3p, miR-720 and The expression levels of miR-144 and miR-1225-3p screened by miRNA chips (AgilentmiRNAs microarray Version 16.0) were quantitatively detected.

[0060] The quantitative results showed that compared with the healthy group, high-risk group and stable angina group, circulating miR-122, miR-140-3p, miR-144, miR-720, miR-1225-3p, miR- The expression levels...

Embodiment 2

[0064] Example 2, the first stage of qRT-PCR analysis to verify the expression difference of the markers of the present invention in individuals with acute coronary syndrome and non-acute coronary syndrome

[0065] Plasma samples were collected from 111 patients between February and March 2012, including 21 cases of non-coronary heart disease, 30 cases of stable angina pectoris, 30 cases of unstable angina pectoris and 30 cases of acute myocardial infarction. There was no significant difference in clinical characteristics between the groups ( See Table 3).

[0066] Table 3. The clinical characteristics of samples from each group of 7 miRNAs verified by the first stage of qRT-PCR analysis

[0067]

[0068]

[0069] The expression levels of miR-3149, miR-122, miR-2861, miR-140-3p, miR-720, miR-144, and miR-1225-3p in plasma were detected by qRT-PCR.

[0070] The results showed that miR-122 and miR-720 in the acute myocardial infarction group were significantly higher than...

Embodiment 3

[0071] Example 3, the second stage of qRT-PCR analysis to verify the expression difference of the markers of the present invention in individuals with acute coronary syndrome and non-acute coronary syndrome

[0072] A further 428 plasma samples were collected from April to August 2012 (51 cases of non-coronary heart disease, 43 cases of stable angina, 257 cases of unstable angina, and 77 cases of acute myocardial infarction). There was no significant difference in clinical characteristics between the groups ( See Table 4).

[0073] Table 4. The second stage verifies the clinical characteristics of each group of samples of miRNAs of the present invention

[0074]

[0075]

[0076] The expressions of miR-122, miR-140-3p, miR-720, miR-2861 and miR-3149 in the above plasma samples were detected by qRT-PCR.

[0077] The results showed that the expression levels of miR-122, miR-140-3p, miR-720, miR-2861 and miR-3149 were significantly higher in the acute coronary syndrome gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides circulating miRNAs (namely microRNAs) for early diagnosis of acute coronary syndromes and an application thereof. The circulating miRNAs comprise miR-3149 and / or miR-122, further comprise miR-2861, and further comprise miR-140-3p and / or miR-720. The circulating miRNAs provided by the invention can be taken as markers to be applied to early diagnosis of the acute coronary syndromes.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to circulating miRNAs for early diagnosis of acute coronary syndrome and related applications. Background technique [0002] Acute coronary syndrome (ACS), including acute myocardial infarction (AMI) and unstable angina (UA), is the most dangerous cardiovascular disease and the leading cause of cardiovascular mortality and morbidity worldwide. In recent years, the incidence of acute coronary syndrome (ACS) in my country has been rapidly increasing. The China Multi-Provincial Cohort Study (CMCS) shows that compared with the Beijing Cardiovascular Disease Population Monitoring (MONICA) study in the early 1990s, the incidence of ACS in my country has nearly doubled, reaching 114 cases / 100,000 person-years . There are 3.5 million patients who die from cardiovascular disease every year in the country, and 700,000 people die from acute coronary syndrome (ACS), which is 7 times th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 顾东风李向东王来元杨跃进黄建凤李宏帆
Owner FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com